Bluebird’s lead CAR-T cancer cell therapy idecabtagene vicleucel (ide-cel) was last year hit with an FDA refuse-to-file letter, which required additional data on chemistry, manufacturing and ...

bluebird bio is to ask regulators to restart clinical studies of its LentiGlobin for sickle cell disease, after an investigation concluded that a case of acute myeloid leukaemia (AML) was "very ...

Apr. 9, 2025 — Astronomers have peered back in time to find what looks like a population of 'hidden' galaxies that could hold the key to unlocking some of the universe's secrets. If their ...